一名接受过多次治疗的转移性结肠癌患者在接受含伊立替康/5-氟尿嘧啶/亚叶酸钙/贝伐单抗治疗后发生致命性肿瘤溶解综合征。 - Suppr

Suppr

超能文献

Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer.

作者信息

Hentrich Marcus, Schiel Xaver, Scheidt Birgit, Reitmeier Michael, Hoffmann Ulrike, Lutz Ludwig

出版信息

Acta Oncol. 2008;47(1):155-6. doi: 10.1080/02841860701460533.

DOI:10.1080/02841860701460533

PMID:18097781

Abstract

摘要

相似文献

Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer.

Acta Oncol. 2008;47(1):155-6. doi: 10.1080/02841860701460533.

Common side effects and interactions of colorectal cancer therapeutic agents.

J Pract Nurs. 2011 Spring;61(1):7-20.

[Systemic therapy for colorectal cancer].

Chirurg. 2005 Jun;76(6):570-2, 574. doi: 10.1007/s00104-005-1038-6.

Bevacizumab in colorectal cancer.

N Engl J Med. 2004 Oct 14;351(16):1690-1; author reply 1690-1.

The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.

Angiogenesis. 2013 Jan;16(1):113-21. doi: 10.1007/s10456-012-9303-z. Epub 2012 Sep 6.

Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.

Jpn J Clin Oncol. 2010 Oct;40(10):933-7. doi: 10.1093/jjco/hyq058. Epub 2010 May 21.

Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.

Clin Colorectal Cancer. 2013 Dec;12(4):239-47. doi: 10.1016/j.clcc.2013.09.001.

[Recent results of irinotecan therapy in colorectal cancer].

Magy Onkol. 2004;48(4):281-8. Epub 2005 Jan 17.

Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.

Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):26-34.

Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.

Clin Oncol (R Coll Radiol). 2011 Sep;23(7):497-8. doi: 10.1016/j.clon.2011.03.009. Epub 2011 May 14.

引用本文的文献

Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases.

Cureus. 2022 Oct 25;14(10):e30652. doi: 10.7759/cureus.30652. eCollection 2022 Oct.

A Retrospective Review of Tumor Lysis Syndrome Associated With Colorectal Cancer.

Cureus. 2020 May 24;12(5):e8257. doi: 10.7759/cureus.8257.

Colorectal Cancer-Associated Spontaneous Tumor Lysis Syndrome: a Case Report and Review of the Current Literature.

J Gastrointest Cancer. 2019 Sep;50(3):668-673. doi: 10.1007/s12029-018-0102-7.

Management of tumour lysis syndrome during first-line palliative chemotherapy for high-volume colorectal cancer.

BMJ Case Rep. 2018 Mar 15;2018:bcr-2017-223474. doi: 10.1136/bcr-2017-223474.

Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib.

J Gastrointest Cancer. 2015 Sep;46(3):314-6. doi: 10.1007/s12029-015-9711-6.

Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature.

Rare Tumors. 2014 Jun 13;6(2):5389. doi: 10.4081/rt.2014.5389. eCollection 2014 May 13.

Tumor lysis syndrome in a patient with metastatic colon cancer after treatment with 5-fluorouracil/leucovorin and oxaliplatin: case report and literature review.

Cancer Res Treat. 2014 Apr;46(2):204-7. doi: 10.4143/crt.2014.46.2.204. Epub 2014 Apr 22.

Postoperative hyperphosphatemia significantly associates with adverse survival in colorectal cancer patients.

J Gastroenterol Hepatol. 2013 Sep;28(9):1469-75. doi: 10.1111/jgh.12237.

An unusual presentation of tumor lysis syndrome in a patient with advanced gastric adenocarcinoma: case report and literature review.

Case Rep Med. 2012;2012:468452. doi: 10.1155/2012/468452. Epub 2012 May 27.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验